article thumbnail

There’s No Clear King of TAVR Valves

CardiacWire

Cardiologists have a wide selection of TAVR valves to choose from, and a new study pitting the top three second generation devices against each other suggests theres not much difference in the long run. So far, we havent known the long-term clinical outcomes of second-generation devices for TAVR beyond five years after implantation.

TAVR 52
article thumbnail

TAVR System Shows Durable Clinical Outcomes, Strong Valve Performance in Low-Risk Aortic Stenosis Patients

DAIC

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Evolut TAVR vs. 9.3% Evolut TAVR vs. 9.3% Grubb, M.D., 1 Herrmann H.

TAVR 52
article thumbnail

Brain-Protected TAVR Results in Fewer Real-World Disabling Strokes

Med Page Today

(MedPage Today) -- NEW YORK CITY -- Researchers eked out evidence of a small clinical benefit with the Sentinel cerebral embolic protection (CEP) device in transcatheter aortic valve replacement (TAVR) -- and pointed to the patients more likely.

TAVR 97
article thumbnail

CLS Health Cardiologists Achieve Historic First with Transcarotid TAVR in Southeast Houston

DAIC

Molham Aldeiri , have successfully performed the first series of transcarotid Transcatheter Aortic Valve Replacement (TAVR) procedures ever done in Southeast Houston. TAVR , whether through the groin approach or neck approach, only requires a half-inch or inch incision.

TAVR 111
article thumbnail

Almost 50% of Patients Under 60 Years Choose TAVR Over Surgical Aortic Valve Replacement with Worse Outcomes

DAIC

From a pool of 37,011 patients, the study identified 2,360 patients under the age of 60 years who underwent these procedures, with 22% receiving TAVR and 78% SAVR. By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. years after TAVR and 4.9 years after TAVR and 4.9

article thumbnail

Evolut Low Risk: TAVR Noninferior to SAVR at 5-Year Follow-Up

American College of Cardiology

Patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke at five years, according to research presented during a Late-Breaking Clinical Trial session at ACC.25 25 in Chicago and simultaneously published in JACC.

TAVR 68
article thumbnail

PROTECTED TAVR: Post Hoc Analysis Suggests Possible Benefits of CEP During TAVR Based on Geographic Region

American College of Cardiology

While the main PROTECTED TAVR trial found no significant differences in stroke rates when cerebral embolic protection (CEP) was used during TAVR compared with TAVR alone, a post hoc analysis of the trial presented during TCT 2024 and simultaneously published in JAMA Cardiology, suggests there may be potential benefits associated with CEP use based (..)

TAVR 48